Loading…
Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial
Patients with HER2-positive breast cancer who have received two or more previous therapies for advanced disease have few effective treatment options. The monarcHER trial aimed to compare the efficacy of abemaciclib plus trastuzumab with or without fulvestrant with standard-of-care chemotherapy of ph...
Saved in:
Published in: | The lancet oncology 2020-06, Vol.21 (6), p.763-775 |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c445t-b05c3b399d88c522756b30ca5e62712d044a8ed8178be766d994efa6d61e0f1b3 |
---|---|
cites | cdi_FETCH-LOGICAL-c445t-b05c3b399d88c522756b30ca5e62712d044a8ed8178be766d994efa6d61e0f1b3 |
container_end_page | 775 |
container_issue | 6 |
container_start_page | 763 |
container_title | The lancet oncology |
container_volume | 21 |
creator | Tolaney, Sara M Wardley, Andrew M Zambelli, Stefania Hilton, John F Troso-Sandoval, Tiffany A Ricci, Francesco Im, Seock-Ah Kim, Sung-Bae Johnston, Stephen RD Chan, Arlene Goel, Shom Catron, Kristen Chapman, Sonya C Price, Gregory L Yang, Zhengyu Gainford, M Corona André, Fabrice |
description | Patients with HER2-positive breast cancer who have received two or more previous therapies for advanced disease have few effective treatment options. The monarcHER trial aimed to compare the efficacy of abemaciclib plus trastuzumab with or without fulvestrant with standard-of-care chemotherapy of physician's choice plus trastuzumab in women with advanced breast cancer.
This phase 2, three-group, open-label trial was done across 75 hospitals, clinics, and medical centres in 14 countries. Eligible patients were women aged 18 years or older, who had hormone receptor-positive, HER2-positive advanced breast cancer with unresectable, locally advanced, recurrent or metastatic disease, Eastern Cooperative Oncology Group performance status of 0 or 1, and who had previously received at least two HER2-targeted therapies for advanced disease. Patients were randomly assigned 1:1:1 to the abemaciclib, trastuzumab, and fulvestrant (group A), abemaciclib and trastuzumab (group B), or standard-of-care chemotherapy and trastuzumab (group C). Oral abemaciclib 150 mg 12 hourly was administered on days 1–21 of a 21-day cycle, intravenous trastuzumab 8 mg/kg on cycle 1 day 1, followed by 6 mg/kg on day 1 of each subsequent 21-day cycle, and intramuscular fulvestrant 500 mg on days 1, 15, and 29 and once every 4 weeks thereafter. Standard-of-care chemotherapy was administered as specified by the product label. Randomisation was by a computer-generated random sequence by means of an interactive web-response system and stratified by number of previous systemic therapies for advanced breast cancer and measurable versus non-measurable disease. The primary endpoint was investigator-assessed progression-free survival in the intention-to-treat population, first testing group A versus group C and, if this result was significant, then group B versus group C. Safety was assessed in all patients who had received at least one dose of study treatment. This trial is registered at ClinicalTrials.gov (NCT02675231) and is ongoing for long-term survival follow-up.
Between May 31, 2016, and Feb 28, 2018, 325 patients were screened, of whom 237 eligible patients were enrolled and randomly assigned to groups A (n=79), B (n=79), and C (n=79). Median follow-up was 19·0 months (IQR 14·7–25·1). The study met its primary endpoint, showing a significant difference at the prespecified two-sided α of 0·2 in median progression-free survival between group A (8·3 months, 95% CI 5·9–12·6) and group C (5·7 month |
doi_str_mv | 10.1016/S1470-2045(20)30112-1 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2425647233</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1470204520301121</els_id><sourcerecordid>2425647233</sourcerecordid><originalsourceid>FETCH-LOGICAL-c445t-b05c3b399d88c522756b30ca5e62712d044a8ed8178be766d994efa6d61e0f1b3</originalsourceid><addsrcrecordid>eNqFkctu1TAQhiMEoqXwCCBLbFrpBHxNcrpBVVUoUiUkLmvLl4niKomD7aQqb80b4JOULtiw8Xis758Zz18Urwl-RzCp3n8jvMYlxVycUnzGMCG0JE-K4_zMS8Gb5ul635Cj4kWMtxiTmmDxvDhilAnGOD0ufl9oGJRxpncaTf0cUQoqpvnXPCiN7lzqkA9r9HNC7dwvEDMxJrRAiP_gqz4mNVoVbOnb0qgAyHQw-NRBUNM9ciO68wOMW-nOh8GPgAIYmJIP5eSjS26BHbq--kofU6TsokYDFukAuR8yhyyg06xWwWT27BwplOeyfnAR7A75CcayVxr6HZo6FQHRPKtT_cviWav6CK8e4knx4-PV98vr8ubLp8-XFzel4VykUmNhmGb7vW0aIyitRaUZNkpARWtCLeZcNWAbUjca6qqy-z2HVlW2IoBbotlJ8XarOwX_c85bk7d-DmNuKSmnouI1ZSxTYqNM8DEGaOUU3KDCvSRYHoyWq9Hy4GI-5Gq0JFn35qH6rAewj6q_zmbgwwZA_uPiIMhoHBx26PK2k7Te_afFH0fbvXw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2425647233</pqid></control><display><type>article</type><title>Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial</title><source>Elsevier</source><creator>Tolaney, Sara M ; Wardley, Andrew M ; Zambelli, Stefania ; Hilton, John F ; Troso-Sandoval, Tiffany A ; Ricci, Francesco ; Im, Seock-Ah ; Kim, Sung-Bae ; Johnston, Stephen RD ; Chan, Arlene ; Goel, Shom ; Catron, Kristen ; Chapman, Sonya C ; Price, Gregory L ; Yang, Zhengyu ; Gainford, M Corona ; André, Fabrice</creator><creatorcontrib>Tolaney, Sara M ; Wardley, Andrew M ; Zambelli, Stefania ; Hilton, John F ; Troso-Sandoval, Tiffany A ; Ricci, Francesco ; Im, Seock-Ah ; Kim, Sung-Bae ; Johnston, Stephen RD ; Chan, Arlene ; Goel, Shom ; Catron, Kristen ; Chapman, Sonya C ; Price, Gregory L ; Yang, Zhengyu ; Gainford, M Corona ; André, Fabrice</creatorcontrib><description>Patients with HER2-positive breast cancer who have received two or more previous therapies for advanced disease have few effective treatment options. The monarcHER trial aimed to compare the efficacy of abemaciclib plus trastuzumab with or without fulvestrant with standard-of-care chemotherapy of physician's choice plus trastuzumab in women with advanced breast cancer.
This phase 2, three-group, open-label trial was done across 75 hospitals, clinics, and medical centres in 14 countries. Eligible patients were women aged 18 years or older, who had hormone receptor-positive, HER2-positive advanced breast cancer with unresectable, locally advanced, recurrent or metastatic disease, Eastern Cooperative Oncology Group performance status of 0 or 1, and who had previously received at least two HER2-targeted therapies for advanced disease. Patients were randomly assigned 1:1:1 to the abemaciclib, trastuzumab, and fulvestrant (group A), abemaciclib and trastuzumab (group B), or standard-of-care chemotherapy and trastuzumab (group C). Oral abemaciclib 150 mg 12 hourly was administered on days 1–21 of a 21-day cycle, intravenous trastuzumab 8 mg/kg on cycle 1 day 1, followed by 6 mg/kg on day 1 of each subsequent 21-day cycle, and intramuscular fulvestrant 500 mg on days 1, 15, and 29 and once every 4 weeks thereafter. Standard-of-care chemotherapy was administered as specified by the product label. Randomisation was by a computer-generated random sequence by means of an interactive web-response system and stratified by number of previous systemic therapies for advanced breast cancer and measurable versus non-measurable disease. The primary endpoint was investigator-assessed progression-free survival in the intention-to-treat population, first testing group A versus group C and, if this result was significant, then group B versus group C. Safety was assessed in all patients who had received at least one dose of study treatment. This trial is registered at ClinicalTrials.gov (NCT02675231) and is ongoing for long-term survival follow-up.
Between May 31, 2016, and Feb 28, 2018, 325 patients were screened, of whom 237 eligible patients were enrolled and randomly assigned to groups A (n=79), B (n=79), and C (n=79). Median follow-up was 19·0 months (IQR 14·7–25·1). The study met its primary endpoint, showing a significant difference at the prespecified two-sided α of 0·2 in median progression-free survival between group A (8·3 months, 95% CI 5·9–12·6) and group C (5·7 months, 5·4–7·0; HR 0·67 [95% CI 0·45–1·00]; p=0·051). No difference was observed between median progression-free survival in group B (5·7 months, 95% CI 4·2–7·2) and group C (HR 0·94 [0·64–1·38]; p=0·77). The most common grade 3–4 treatment-emergent adverse event in groups A, B, and C was neutropenia (21 [27%] of 78 patients, 17 [22%] of 77, and 19 [26%] of 72). The most common serious adverse events were: in group A, pyrexia (three [4%]), diarrhoea (two [3%]), urinary tract infection (two [3%]), and acute kidney injury (two [3%]); in group B, diarrhoea (two [3%]) and pneumonitis (two [3%]); and in group C, neutropenia (four [6%]) and pleural effusion (two [3%]). Two deaths were attributed to treatment: one due to pulmonary fibrosis in group B and one due to febrile neutropenia in group C.
The combination of abemaciclib, fulvestrant, and trastuzumab significantly improved progression-free survival versus standard-of-care chemotherapy plus trastuzumab while showing a tolerable safety profile. Our results suggest that a chemotherapy-free regimen might potentially be an alternative treatment option for patients with hormone receptor-positive, HER2-positive advanced breast cancer.
Eli Lilly and Company.</description><identifier>ISSN: 1470-2045</identifier><identifier>EISSN: 1474-5488</identifier><identifier>DOI: 10.1016/S1470-2045(20)30112-1</identifier><identifier>PMID: 32353342</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject><![CDATA[Aged ; Aminopyridines - administration & dosage ; Aminopyridines - adverse effects ; Antineoplastic Agents, Immunological - administration & dosage ; Antineoplastic Agents, Immunological - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Argentina ; Australia ; Benzimidazoles - administration & dosage ; Benzimidazoles - adverse effects ; Brazil ; Breast cancer ; Breast Neoplasms - drug therapy ; Breast Neoplasms - enzymology ; Breast Neoplasms - mortality ; Breast Neoplasms - pathology ; Cancer therapies ; Chemotherapy ; Cyclin-dependent kinases ; Cytotoxicity ; Diarrhea ; Disease Progression ; Endocrine therapy ; ErbB-2 protein ; Estrogen Receptor Antagonists - administration & dosage ; Estrogen Receptor Antagonists - adverse effects ; Europe ; Female ; Fever ; Fibrosis ; Fulvestrant ; Fulvestrant - administration & dosage ; Fulvestrant - adverse effects ; Humans ; Immunotherapy ; Intravenous administration ; Lung diseases ; Metastases ; Metastasis ; Middle Aged ; Monoclonal antibodies ; Neutropenia ; North America ; Oncology ; Patients ; Pleural effusion ; Pneumonitis ; Progression-Free Survival ; Protein Kinase Inhibitors - administration & dosage ; Protein Kinase Inhibitors - adverse effects ; Receptor, ErbB-2 - antagonists & inhibitors ; Receptor, ErbB-2 - metabolism ; Receptors, Estrogen - drug effects ; Receptors, Estrogen - metabolism ; Receptors, Progesterone - metabolism ; Republic of Korea ; Signal Transduction ; Standard of care ; Studies ; Survival ; Targeted cancer therapy ; Time Factors ; Trastuzumab ; Trastuzumab - administration & dosage ; Trastuzumab - adverse effects ; Urinary tract ; Womens health]]></subject><ispartof>The lancet oncology, 2020-06, Vol.21 (6), p.763-775</ispartof><rights>2020 Elsevier Ltd</rights><rights>Copyright © 2020 Elsevier Ltd. All rights reserved.</rights><rights>2020. Elsevier Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c445t-b05c3b399d88c522756b30ca5e62712d044a8ed8178be766d994efa6d61e0f1b3</citedby><cites>FETCH-LOGICAL-c445t-b05c3b399d88c522756b30ca5e62712d044a8ed8178be766d994efa6d61e0f1b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32353342$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tolaney, Sara M</creatorcontrib><creatorcontrib>Wardley, Andrew M</creatorcontrib><creatorcontrib>Zambelli, Stefania</creatorcontrib><creatorcontrib>Hilton, John F</creatorcontrib><creatorcontrib>Troso-Sandoval, Tiffany A</creatorcontrib><creatorcontrib>Ricci, Francesco</creatorcontrib><creatorcontrib>Im, Seock-Ah</creatorcontrib><creatorcontrib>Kim, Sung-Bae</creatorcontrib><creatorcontrib>Johnston, Stephen RD</creatorcontrib><creatorcontrib>Chan, Arlene</creatorcontrib><creatorcontrib>Goel, Shom</creatorcontrib><creatorcontrib>Catron, Kristen</creatorcontrib><creatorcontrib>Chapman, Sonya C</creatorcontrib><creatorcontrib>Price, Gregory L</creatorcontrib><creatorcontrib>Yang, Zhengyu</creatorcontrib><creatorcontrib>Gainford, M Corona</creatorcontrib><creatorcontrib>André, Fabrice</creatorcontrib><title>Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial</title><title>The lancet oncology</title><addtitle>Lancet Oncol</addtitle><description>Patients with HER2-positive breast cancer who have received two or more previous therapies for advanced disease have few effective treatment options. The monarcHER trial aimed to compare the efficacy of abemaciclib plus trastuzumab with or without fulvestrant with standard-of-care chemotherapy of physician's choice plus trastuzumab in women with advanced breast cancer.
This phase 2, three-group, open-label trial was done across 75 hospitals, clinics, and medical centres in 14 countries. Eligible patients were women aged 18 years or older, who had hormone receptor-positive, HER2-positive advanced breast cancer with unresectable, locally advanced, recurrent or metastatic disease, Eastern Cooperative Oncology Group performance status of 0 or 1, and who had previously received at least two HER2-targeted therapies for advanced disease. Patients were randomly assigned 1:1:1 to the abemaciclib, trastuzumab, and fulvestrant (group A), abemaciclib and trastuzumab (group B), or standard-of-care chemotherapy and trastuzumab (group C). Oral abemaciclib 150 mg 12 hourly was administered on days 1–21 of a 21-day cycle, intravenous trastuzumab 8 mg/kg on cycle 1 day 1, followed by 6 mg/kg on day 1 of each subsequent 21-day cycle, and intramuscular fulvestrant 500 mg on days 1, 15, and 29 and once every 4 weeks thereafter. Standard-of-care chemotherapy was administered as specified by the product label. Randomisation was by a computer-generated random sequence by means of an interactive web-response system and stratified by number of previous systemic therapies for advanced breast cancer and measurable versus non-measurable disease. The primary endpoint was investigator-assessed progression-free survival in the intention-to-treat population, first testing group A versus group C and, if this result was significant, then group B versus group C. Safety was assessed in all patients who had received at least one dose of study treatment. This trial is registered at ClinicalTrials.gov (NCT02675231) and is ongoing for long-term survival follow-up.
Between May 31, 2016, and Feb 28, 2018, 325 patients were screened, of whom 237 eligible patients were enrolled and randomly assigned to groups A (n=79), B (n=79), and C (n=79). Median follow-up was 19·0 months (IQR 14·7–25·1). The study met its primary endpoint, showing a significant difference at the prespecified two-sided α of 0·2 in median progression-free survival between group A (8·3 months, 95% CI 5·9–12·6) and group C (5·7 months, 5·4–7·0; HR 0·67 [95% CI 0·45–1·00]; p=0·051). No difference was observed between median progression-free survival in group B (5·7 months, 95% CI 4·2–7·2) and group C (HR 0·94 [0·64–1·38]; p=0·77). The most common grade 3–4 treatment-emergent adverse event in groups A, B, and C was neutropenia (21 [27%] of 78 patients, 17 [22%] of 77, and 19 [26%] of 72). The most common serious adverse events were: in group A, pyrexia (three [4%]), diarrhoea (two [3%]), urinary tract infection (two [3%]), and acute kidney injury (two [3%]); in group B, diarrhoea (two [3%]) and pneumonitis (two [3%]); and in group C, neutropenia (four [6%]) and pleural effusion (two [3%]). Two deaths were attributed to treatment: one due to pulmonary fibrosis in group B and one due to febrile neutropenia in group C.
The combination of abemaciclib, fulvestrant, and trastuzumab significantly improved progression-free survival versus standard-of-care chemotherapy plus trastuzumab while showing a tolerable safety profile. Our results suggest that a chemotherapy-free regimen might potentially be an alternative treatment option for patients with hormone receptor-positive, HER2-positive advanced breast cancer.
Eli Lilly and Company.</description><subject>Aged</subject><subject>Aminopyridines - administration & dosage</subject><subject>Aminopyridines - adverse effects</subject><subject>Antineoplastic Agents, Immunological - administration & dosage</subject><subject>Antineoplastic Agents, Immunological - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Argentina</subject><subject>Australia</subject><subject>Benzimidazoles - administration & dosage</subject><subject>Benzimidazoles - adverse effects</subject><subject>Brazil</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Breast Neoplasms - enzymology</subject><subject>Breast Neoplasms - mortality</subject><subject>Breast Neoplasms - pathology</subject><subject>Cancer therapies</subject><subject>Chemotherapy</subject><subject>Cyclin-dependent kinases</subject><subject>Cytotoxicity</subject><subject>Diarrhea</subject><subject>Disease Progression</subject><subject>Endocrine therapy</subject><subject>ErbB-2 protein</subject><subject>Estrogen Receptor Antagonists - administration & dosage</subject><subject>Estrogen Receptor Antagonists - adverse effects</subject><subject>Europe</subject><subject>Female</subject><subject>Fever</subject><subject>Fibrosis</subject><subject>Fulvestrant</subject><subject>Fulvestrant - administration & dosage</subject><subject>Fulvestrant - adverse effects</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>Intravenous administration</subject><subject>Lung diseases</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Middle Aged</subject><subject>Monoclonal antibodies</subject><subject>Neutropenia</subject><subject>North America</subject><subject>Oncology</subject><subject>Patients</subject><subject>Pleural effusion</subject><subject>Pneumonitis</subject><subject>Progression-Free Survival</subject><subject>Protein Kinase Inhibitors - administration & dosage</subject><subject>Protein Kinase Inhibitors - adverse effects</subject><subject>Receptor, ErbB-2 - antagonists & inhibitors</subject><subject>Receptor, ErbB-2 - metabolism</subject><subject>Receptors, Estrogen - drug effects</subject><subject>Receptors, Estrogen - metabolism</subject><subject>Receptors, Progesterone - metabolism</subject><subject>Republic of Korea</subject><subject>Signal Transduction</subject><subject>Standard of care</subject><subject>Studies</subject><subject>Survival</subject><subject>Targeted cancer therapy</subject><subject>Time Factors</subject><subject>Trastuzumab</subject><subject>Trastuzumab - administration & dosage</subject><subject>Trastuzumab - adverse effects</subject><subject>Urinary tract</subject><subject>Womens health</subject><issn>1470-2045</issn><issn>1474-5488</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNqFkctu1TAQhiMEoqXwCCBLbFrpBHxNcrpBVVUoUiUkLmvLl4niKomD7aQqb80b4JOULtiw8Xis758Zz18Urwl-RzCp3n8jvMYlxVycUnzGMCG0JE-K4_zMS8Gb5ul635Cj4kWMtxiTmmDxvDhilAnGOD0ufl9oGJRxpncaTf0cUQoqpvnXPCiN7lzqkA9r9HNC7dwvEDMxJrRAiP_gqz4mNVoVbOnb0qgAyHQw-NRBUNM9ciO68wOMW-nOh8GPgAIYmJIP5eSjS26BHbq--kofU6TsokYDFukAuR8yhyyg06xWwWT27BwplOeyfnAR7A75CcayVxr6HZo6FQHRPKtT_cviWav6CK8e4knx4-PV98vr8ubLp8-XFzel4VykUmNhmGb7vW0aIyitRaUZNkpARWtCLeZcNWAbUjca6qqy-z2HVlW2IoBbotlJ8XarOwX_c85bk7d-DmNuKSmnouI1ZSxTYqNM8DEGaOUU3KDCvSRYHoyWq9Hy4GI-5Gq0JFn35qH6rAewj6q_zmbgwwZA_uPiIMhoHBx26PK2k7Te_afFH0fbvXw</recordid><startdate>202006</startdate><enddate>202006</enddate><creator>Tolaney, Sara M</creator><creator>Wardley, Andrew M</creator><creator>Zambelli, Stefania</creator><creator>Hilton, John F</creator><creator>Troso-Sandoval, Tiffany A</creator><creator>Ricci, Francesco</creator><creator>Im, Seock-Ah</creator><creator>Kim, Sung-Bae</creator><creator>Johnston, Stephen RD</creator><creator>Chan, Arlene</creator><creator>Goel, Shom</creator><creator>Catron, Kristen</creator><creator>Chapman, Sonya C</creator><creator>Price, Gregory L</creator><creator>Yang, Zhengyu</creator><creator>Gainford, M Corona</creator><creator>André, Fabrice</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>3V.</scope><scope>7RV</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8C2</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>202006</creationdate><title>Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial</title><author>Tolaney, Sara M ; Wardley, Andrew M ; Zambelli, Stefania ; Hilton, John F ; Troso-Sandoval, Tiffany A ; Ricci, Francesco ; Im, Seock-Ah ; Kim, Sung-Bae ; Johnston, Stephen RD ; Chan, Arlene ; Goel, Shom ; Catron, Kristen ; Chapman, Sonya C ; Price, Gregory L ; Yang, Zhengyu ; Gainford, M Corona ; André, Fabrice</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c445t-b05c3b399d88c522756b30ca5e62712d044a8ed8178be766d994efa6d61e0f1b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Aged</topic><topic>Aminopyridines - administration & dosage</topic><topic>Aminopyridines - adverse effects</topic><topic>Antineoplastic Agents, Immunological - administration & dosage</topic><topic>Antineoplastic Agents, Immunological - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Argentina</topic><topic>Australia</topic><topic>Benzimidazoles - administration & dosage</topic><topic>Benzimidazoles - adverse effects</topic><topic>Brazil</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Breast Neoplasms - enzymology</topic><topic>Breast Neoplasms - mortality</topic><topic>Breast Neoplasms - pathology</topic><topic>Cancer therapies</topic><topic>Chemotherapy</topic><topic>Cyclin-dependent kinases</topic><topic>Cytotoxicity</topic><topic>Diarrhea</topic><topic>Disease Progression</topic><topic>Endocrine therapy</topic><topic>ErbB-2 protein</topic><topic>Estrogen Receptor Antagonists - administration & dosage</topic><topic>Estrogen Receptor Antagonists - adverse effects</topic><topic>Europe</topic><topic>Female</topic><topic>Fever</topic><topic>Fibrosis</topic><topic>Fulvestrant</topic><topic>Fulvestrant - administration & dosage</topic><topic>Fulvestrant - adverse effects</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>Intravenous administration</topic><topic>Lung diseases</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Middle Aged</topic><topic>Monoclonal antibodies</topic><topic>Neutropenia</topic><topic>North America</topic><topic>Oncology</topic><topic>Patients</topic><topic>Pleural effusion</topic><topic>Pneumonitis</topic><topic>Progression-Free Survival</topic><topic>Protein Kinase Inhibitors - administration & dosage</topic><topic>Protein Kinase Inhibitors - adverse effects</topic><topic>Receptor, ErbB-2 - antagonists & inhibitors</topic><topic>Receptor, ErbB-2 - metabolism</topic><topic>Receptors, Estrogen - drug effects</topic><topic>Receptors, Estrogen - metabolism</topic><topic>Receptors, Progesterone - metabolism</topic><topic>Republic of Korea</topic><topic>Signal Transduction</topic><topic>Standard of care</topic><topic>Studies</topic><topic>Survival</topic><topic>Targeted cancer therapy</topic><topic>Time Factors</topic><topic>Trastuzumab</topic><topic>Trastuzumab - administration & dosage</topic><topic>Trastuzumab - adverse effects</topic><topic>Urinary tract</topic><topic>Womens health</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tolaney, Sara M</creatorcontrib><creatorcontrib>Wardley, Andrew M</creatorcontrib><creatorcontrib>Zambelli, Stefania</creatorcontrib><creatorcontrib>Hilton, John F</creatorcontrib><creatorcontrib>Troso-Sandoval, Tiffany A</creatorcontrib><creatorcontrib>Ricci, Francesco</creatorcontrib><creatorcontrib>Im, Seock-Ah</creatorcontrib><creatorcontrib>Kim, Sung-Bae</creatorcontrib><creatorcontrib>Johnston, Stephen RD</creatorcontrib><creatorcontrib>Chan, Arlene</creatorcontrib><creatorcontrib>Goel, Shom</creatorcontrib><creatorcontrib>Catron, Kristen</creatorcontrib><creatorcontrib>Chapman, Sonya C</creatorcontrib><creatorcontrib>Price, Gregory L</creatorcontrib><creatorcontrib>Yang, Zhengyu</creatorcontrib><creatorcontrib>Gainford, M Corona</creatorcontrib><creatorcontrib>André, Fabrice</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Lancet Titles</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>The lancet oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tolaney, Sara M</au><au>Wardley, Andrew M</au><au>Zambelli, Stefania</au><au>Hilton, John F</au><au>Troso-Sandoval, Tiffany A</au><au>Ricci, Francesco</au><au>Im, Seock-Ah</au><au>Kim, Sung-Bae</au><au>Johnston, Stephen RD</au><au>Chan, Arlene</au><au>Goel, Shom</au><au>Catron, Kristen</au><au>Chapman, Sonya C</au><au>Price, Gregory L</au><au>Yang, Zhengyu</au><au>Gainford, M Corona</au><au>André, Fabrice</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial</atitle><jtitle>The lancet oncology</jtitle><addtitle>Lancet Oncol</addtitle><date>2020-06</date><risdate>2020</risdate><volume>21</volume><issue>6</issue><spage>763</spage><epage>775</epage><pages>763-775</pages><issn>1470-2045</issn><eissn>1474-5488</eissn><abstract>Patients with HER2-positive breast cancer who have received two or more previous therapies for advanced disease have few effective treatment options. The monarcHER trial aimed to compare the efficacy of abemaciclib plus trastuzumab with or without fulvestrant with standard-of-care chemotherapy of physician's choice plus trastuzumab in women with advanced breast cancer.
This phase 2, three-group, open-label trial was done across 75 hospitals, clinics, and medical centres in 14 countries. Eligible patients were women aged 18 years or older, who had hormone receptor-positive, HER2-positive advanced breast cancer with unresectable, locally advanced, recurrent or metastatic disease, Eastern Cooperative Oncology Group performance status of 0 or 1, and who had previously received at least two HER2-targeted therapies for advanced disease. Patients were randomly assigned 1:1:1 to the abemaciclib, trastuzumab, and fulvestrant (group A), abemaciclib and trastuzumab (group B), or standard-of-care chemotherapy and trastuzumab (group C). Oral abemaciclib 150 mg 12 hourly was administered on days 1–21 of a 21-day cycle, intravenous trastuzumab 8 mg/kg on cycle 1 day 1, followed by 6 mg/kg on day 1 of each subsequent 21-day cycle, and intramuscular fulvestrant 500 mg on days 1, 15, and 29 and once every 4 weeks thereafter. Standard-of-care chemotherapy was administered as specified by the product label. Randomisation was by a computer-generated random sequence by means of an interactive web-response system and stratified by number of previous systemic therapies for advanced breast cancer and measurable versus non-measurable disease. The primary endpoint was investigator-assessed progression-free survival in the intention-to-treat population, first testing group A versus group C and, if this result was significant, then group B versus group C. Safety was assessed in all patients who had received at least one dose of study treatment. This trial is registered at ClinicalTrials.gov (NCT02675231) and is ongoing for long-term survival follow-up.
Between May 31, 2016, and Feb 28, 2018, 325 patients were screened, of whom 237 eligible patients were enrolled and randomly assigned to groups A (n=79), B (n=79), and C (n=79). Median follow-up was 19·0 months (IQR 14·7–25·1). The study met its primary endpoint, showing a significant difference at the prespecified two-sided α of 0·2 in median progression-free survival between group A (8·3 months, 95% CI 5·9–12·6) and group C (5·7 months, 5·4–7·0; HR 0·67 [95% CI 0·45–1·00]; p=0·051). No difference was observed between median progression-free survival in group B (5·7 months, 95% CI 4·2–7·2) and group C (HR 0·94 [0·64–1·38]; p=0·77). The most common grade 3–4 treatment-emergent adverse event in groups A, B, and C was neutropenia (21 [27%] of 78 patients, 17 [22%] of 77, and 19 [26%] of 72). The most common serious adverse events were: in group A, pyrexia (three [4%]), diarrhoea (two [3%]), urinary tract infection (two [3%]), and acute kidney injury (two [3%]); in group B, diarrhoea (two [3%]) and pneumonitis (two [3%]); and in group C, neutropenia (four [6%]) and pleural effusion (two [3%]). Two deaths were attributed to treatment: one due to pulmonary fibrosis in group B and one due to febrile neutropenia in group C.
The combination of abemaciclib, fulvestrant, and trastuzumab significantly improved progression-free survival versus standard-of-care chemotherapy plus trastuzumab while showing a tolerable safety profile. Our results suggest that a chemotherapy-free regimen might potentially be an alternative treatment option for patients with hormone receptor-positive, HER2-positive advanced breast cancer.
Eli Lilly and Company.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>32353342</pmid><doi>10.1016/S1470-2045(20)30112-1</doi><tpages>13</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1470-2045 |
ispartof | The lancet oncology, 2020-06, Vol.21 (6), p.763-775 |
issn | 1470-2045 1474-5488 |
language | eng |
recordid | cdi_proquest_journals_2425647233 |
source | Elsevier |
subjects | Aged Aminopyridines - administration & dosage Aminopyridines - adverse effects Antineoplastic Agents, Immunological - administration & dosage Antineoplastic Agents, Immunological - adverse effects Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Argentina Australia Benzimidazoles - administration & dosage Benzimidazoles - adverse effects Brazil Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - enzymology Breast Neoplasms - mortality Breast Neoplasms - pathology Cancer therapies Chemotherapy Cyclin-dependent kinases Cytotoxicity Diarrhea Disease Progression Endocrine therapy ErbB-2 protein Estrogen Receptor Antagonists - administration & dosage Estrogen Receptor Antagonists - adverse effects Europe Female Fever Fibrosis Fulvestrant Fulvestrant - administration & dosage Fulvestrant - adverse effects Humans Immunotherapy Intravenous administration Lung diseases Metastases Metastasis Middle Aged Monoclonal antibodies Neutropenia North America Oncology Patients Pleural effusion Pneumonitis Progression-Free Survival Protein Kinase Inhibitors - administration & dosage Protein Kinase Inhibitors - adverse effects Receptor, ErbB-2 - antagonists & inhibitors Receptor, ErbB-2 - metabolism Receptors, Estrogen - drug effects Receptors, Estrogen - metabolism Receptors, Progesterone - metabolism Republic of Korea Signal Transduction Standard of care Studies Survival Targeted cancer therapy Time Factors Trastuzumab Trastuzumab - administration & dosage Trastuzumab - adverse effects Urinary tract Womens health |
title | Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T17%3A44%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Abemaciclib%20plus%20trastuzumab%20with%20or%20without%20fulvestrant%20versus%20trastuzumab%20plus%20standard-of-care%20chemotherapy%20in%20women%20with%20hormone%20receptor-positive,%20HER2-positive%20advanced%20breast%20cancer%20(monarcHER):%20a%20randomised,%20open-label,%20phase%202%20trial&rft.jtitle=The%20lancet%20oncology&rft.au=Tolaney,%20Sara%20M&rft.date=2020-06&rft.volume=21&rft.issue=6&rft.spage=763&rft.epage=775&rft.pages=763-775&rft.issn=1470-2045&rft.eissn=1474-5488&rft_id=info:doi/10.1016/S1470-2045(20)30112-1&rft_dat=%3Cproquest_cross%3E2425647233%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c445t-b05c3b399d88c522756b30ca5e62712d044a8ed8178be766d994efa6d61e0f1b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2425647233&rft_id=info:pmid/32353342&rfr_iscdi=true |